This technology identifies proteases that are essential for infection and propagation of the human parainfluenza virus (HPIV) in the lung and describes a method of treating HPIV with serine protease inhibitors.
There are currently no vaccines and treatments for the human parainfluenza virus (HPIV). The mechanisms of activation and propagation of HPIV3 in the lung is poorly understood. Thus, elucidating the essential factors of HPIV3 spread the mechanisms of propagation may identify methods for HPIV3 treatment.
This technology identifies two serine proteases that cleave viral furin proteins to allow the spread and proliferation of the human parainfluenza virus in the human lung. Facilitation of transmembrane proteases that target TMPRSS2 and TMPRSS4 expression are important for cleavage of HPIV3 fusion protein in the human lung. Serine protease inhibitors, including nafamostat, reduced HPIV3 spread in nasal tissue of cotton rats and thus may be utilized as methods to prevent or treat HPIV.
This technology has been validated in vivo in cotton rats.
Patent Pending (WO/2023/220712)
IR CU22326
Licensing Contact: Kristin Neuman